Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.

Trial Profile

201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.

Status: Completed
Phase of Trial: Phase III/IV

Latest Information Update: 07 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abacavir/dolutegravir/lamivudine (Primary) ; Antiretrovirals; Atazanavir; Elvitegravir; Raltegravir
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms STRIIVING
  • Sponsors GlaxoSmithKline; ViiV Healthcare
  • Most Recent Events

    • 07 Mar 2019 Results assessing associated with HOMA-IR (homeostasis model of assessment -insulin resistance) and effect of dolutegravir over time from SPRING-1, STRIIVING, SWORD-1 and -2 trials presented at the 26th Conference on Retroviruses and Opportunistic Infections
    • 31 Aug 2018 Biomarkers information updated
    • 25 Feb 2016 Results presented at the 23rd Conference on Retroviruses and Opportunistic Infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top